Pharmafile Logo
Pharmafocus logo
Advanced Search

Johnson & Johnson

Showing 15 posts of 132 posts found.

Making strides in hepatitis

June 19, 2017
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Janssen, Johnson & Johnson

Pharmafocus caughtup with Lawrence Blatt, Janssen’s Global Therapeutic Area Head, Infectious Diseases and Vaccines, to discuss the progress being made in the …

Feature
aging_-_hand

Latest prostate cancer research could provide boost for J&J

June 5, 2017
Research and Development, Sales and Marketing CRUK, Cancer, Johnson & Johnson, prostate cancer

Research funded by Cancer Research UK has found that abiraterone added to hormone therapy improved survival by over a third …

News
janeg

J&J lines up its Global Head for Actelion

May 22, 2017
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Actelion, Janssen, Johnson & Johnson

The deal is not yet complete but the last steps are assumed to be a formality – at least Johnson …

Appointment

FDA demands new warnings for J&J diabetes drug over amputation risk

May 17, 2017
Manufacturing and Production, Research and Development, Sales and Marketing J&J, JJ, Johnson & Johnson, diabetes

Johnson & Johnson has found itself in deep water again over the potentially harmful effects of its products. This time …

News
talc_mine

J&J chalks up another defeat in $110 million talc-cancer case

May 5, 2017
Medical Communications Johnson & Johnson, baby powder

Johnson & Johnson has suffered another defeat in a lawsuit against its talcum powder product. The latest case stands as …

News
embotrap

J&J acquires Neuravi to bolster neuro business

April 11, 2017
Manufacturing and Production, Sales and Marketing Johnson & Johnson, Neuravi

Johnson & Johnson’s neurosurgery and neurovascular unit, Codman Neuro, has made the move to acquire Galway-based company, Neuravi. The exact …

News
actelion

EMA green lights Actelion’s drug after patient deaths scare

April 10, 2017
Sales and Marketing Actelion, Johnson & Johnson, Uptravi

The EMA has ruled that the five patient deaths that occurred in February of this year were not directly related …

News

Closure of Scottish J&J plant threatens 400 staff

March 10, 2017
Manufacturing and Production, Medical Communications J&J, JJ, Johnson & Johnson

Johnson & Johnson has announced its intention to shut down its surgical suture manufacturing facility in Livingston, Scotland which sees …

News
jj_2johnson_and_johnson

J&J latest pharma firm to volunteer pricing data

February 28, 2017
Manufacturing and Production, Medical Communications J&J, JJ, Johnson & Johnson

Johnson & Johnson released its pricing data, as promised, in February and it has simply revealed that its average price …

News
pfizer_brussels

Pfizer’s Remicade biosimilar displays similar efficacy

February 22, 2017
Research and Development Johnson & Johnson, Pfizer, Remicade, inflectra

Pfizer and Celltrion have announced new data for their Remicade biosimilar, Inflectra, that shows that the drug is comparable in …

News
pharmafocus_march_cover

The March 2017 issue of Pharmafocus is now live!

February 22, 2017
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Actelion, FDA, Johnson & Johnson, MSD, Roche, Trump, crispr, immunotherapy, opdivo

The latest edition of Pharmafocus is available to read online now! From breakthroughs in antibiotic resistance R&D to gene editing …

News
handshake-2056023_960_720

Integra bids $1.045 billion for J&J’s neurosurgery business

February 16, 2017
Sales and Marketing Codman, Integra, J&J, JJ, Johnson & Johnson

Integra, a medical technology company, have announced that it has made a binding offer to acquire Johnson & Johnson’s Codman …

News
money-256281_960_720

Five most talked about mergers and acquisitions of 2016

January 27, 2017
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Actavis, Bayer, Boehringer, Johnson & Johnson, Sanofi, Teva, acquisition, mergers, monsanto, pharma

2017 has kicked off with a bang – as Johnson & Johnson confirmed a $30 billion deal to takeover of …

Feature
jj

J&J finally seals $30 billion deal for Actelion

January 26, 2017
Sales and Marketing Actelion, Janssen, Johnson & Johnson

Johnson & Johnson has, as expected, wrapped up the deal to acquire Actelion in a deal worth $30 billion, working …

News
jj_sign_on_wall

J&J to reveal drug price increases next month

January 16, 2017
Sales and Marketing Johnson & Johnson

Next month, Johnson & Johnson will reveal the average price increases of its prescription drugs in a move to increase …

News

Latest content

Regeneron shares data for multiple myeloma treatment

December 8, 2023

Merck collaborates with Acceleration Consortium for AI experimentation

December 8, 2023

AbbVie to acquire Cerevel Therapeutics for approximately $8.7bn

December 7, 2023

ONK Therapeutics and NAYA Biosciences enter partnership for NK cell therapy development

December 7, 2023

FDA approves Novartis’ Fabhalta for PNH treatment

December 6, 2023